|
注册号: Registration number: |
ChiCTR2300068720 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-22 20:28:18 |
|
注册时间: Date of Registration: |
2023-02-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
临床药师对中重度特应性皮炎患者实施标准化药物治疗管理服务的效果评价 |
|
Public title: |
Evaluation of clinical pharmacists implementing standardized drug therapy management services for patients with moderate to severe atopic dermatitis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
临床药师对中重度特应性皮炎患者实施标准化药物治疗管理服务的效果评价 |
|
Scientific title: |
Evaluation of clinical pharmacists implementing standardized drug therapy management services for patients with moderate to severe atopic dermatitis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
信如娟 |
研究负责人: |
朱全刚 |
|
Applicant: |
Xin Rujuan |
Study leader: |
Zhu Quangang |
|
申请注册联系人电话: Applicant telephone: |
+86 189 3983 9316 |
研究负责人电话:
Study leader's |
+86 180 1733 6652 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xinrujuan1112@126.com |
研究负责人电子邮件: Study leader's E-mail: |
qgzhu@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区保德路1278号 |
研究负责人通讯地址: |
上海市静安区保德路1278号 |
|
Applicant address: |
1278 Baode Road, Jing 'an District, Shanghai |
Study leader's address: |
1278 Baode Road, Jing 'an District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市皮肤病医院 |
||
|
Applicant's institution: |
shanghai skin disease hospital |
||
|
研究负责人所在单位: |
上海市皮肤病医院 |
||
|
Affiliation of the Leader: |
shanghai skin disease hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-28(科) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市皮肤病医院临床试验伦理委员会 |
||
|
Name of the ethic committee: |
Shanghai Dermatology Hospital Clinical Trial Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-09-16 00:00:00 | ||
|
伦理委员会联系人: |
刘硕 |
||
|
Contact Name of the ethic committee: |
liushuo |
||
|
伦理委员会联系地址: |
上海市静安区保德路1278号 |
||
|
Contact Address of the ethic committee: |
1278 Baode Road, Jing 'an District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 36803156 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市皮肤病医院 |
||||||||||||||||||||||
|
Primary sponsor: |
shanghai skin disease hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市静安区保德路1278号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1278 Baode Road, Jing 'an District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中关村助帮医疗健康科技创新中心 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhongguancun Help Bang Medical health Technology Innovation Center |
||||||||||||||||||||||
|
研究疾病: |
特应性皮炎 |
||||||||||||||||||||||
|
Target disease: |
atopic dermatitis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价临床药师按照既定的《药学服务标准与路径》,对中重度AD成年患者实施标准化MTM服务对相关治疗有效性的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effect of clinical pharmacists implementing standardized MTM services for adult patients with moderate to severe AD in accordance with established Standards and Pathways for Pharmaceutical Care on the effectiveness of relevant treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.入组前28天,受试者参加了其他临床试验项目; 2.处于放化疗、靶向治疗、免疫治疗、细胞治疗期间的恶性肿瘤或血液病患者; 3.计划在研究期间进行重大手术的患者; 4.伴有不稳定精神疾病、酗酒、吸毒或药物滥用等情况的受试者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. 28 days before enrollment, the subjects participated in other clinical trial projects; 2. Patients with malignant tumors or hematological diseases who are undergoing radiotherapy, chemotherapy, Targeted therapy, immunotherapy, and cell therapy; 3. Patients planning to undergo major surgeries during the study period; 4. Subjects with unstable mental illness, alcoholism, drug abuse, or other conditions. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-02-02 00:00:00至 To 2024-02-02 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-02-28 00:00:00 至 To 2024-02-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用分层随机,分层因素为AD分级(3级或4级),通过主中心预制随机分配表实现各中心随机分组。随机分配表应有独立于研究者(临床药师)的统计师掌握,并在整个研究过程中保密。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Hierarchical randomization is adopted. The hierarchical factor is AD hierarchical (level 3 or level 4). The prefabricated random allocation table of the main center is used to implement random grouping of the centers. The random assignment table should be held by a statistician independent of the investigator ( |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
否 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |